ARTICLE | Clinical News

Resminostat: Phase I data

October 6, 2014 7:00 AM UTC

Data from 9 patients with previously untreated advanced HCC in the dose-escalation Phase I portion of a Japanese Phase I/II trial showed that resminostat plus sorafenib was well tolerated. Based on the results, Yakult Honsha started the randomized Phase II portion to compare resminostat plus sorafenib vs. sorafenib alone as first-line treatment in up to 140 patients with advanced HCC. ...